Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine Selects Pfdhfr-dhps Quintuple Mutant Genotype in Mali

Hamma Maiga, Estrella Lasry, Modibo Diarra, Issaka Sagara, Amadou Bamadio, Aliou Traore, Samba Coumare, Soma Bahonan, Boubou Sangare, Yeyia Dicko, Nouhoum Diallo, Aly Tembely, Djibril Traore, Hamidou Niangaly, François Dao, Aboubecrine Haidara, Alassane Dicko, Ogobara K Doumbo, Abdoulaye A Djimde, Hamma Maiga, Estrella Lasry, Modibo Diarra, Issaka Sagara, Amadou Bamadio, Aliou Traore, Samba Coumare, Soma Bahonan, Boubou Sangare, Yeyia Dicko, Nouhoum Diallo, Aly Tembely, Djibril Traore, Hamidou Niangaly, François Dao, Aboubecrine Haidara, Alassane Dicko, Ogobara K Doumbo, Abdoulaye A Djimde

Abstract

Background: Seasonal malaria chemoprevention (SMC) with sulphadoxine-pyrimethamine (SP) plus amodiaquine (AQ) is being scaled up in Sahelian countries of West Africa. However, the potential development of Plasmodium falciparum resistance to the respective component drugs is a major concern.

Methods: Two cross-sectional surveys were conducted before (August 2012) and after (June 2014) a pilot implementation of SMC in Koutiala, Mali. Children aged 3-59 months received 7 rounds of curative doses of SP plus AQ over two malaria seasons. Genotypes of P. falciparum Pfdhfr codons 51, 59 and 108; Pfdhps codons 437 and 540, Pfcrt codon 76 and Pfmdr1codon 86 were analyzed by PCR on DNA from samples collected before and after SMC, and in non-SMC patient population as controls (November 2014).

Results: In the SMC population 191/662 (28.9%) and 85/670 (12.7%) of children were P. falciparum positive by microscopy and were included in the molecular analysis before (2012) and after SMC implementation (2014), respectively. In the non-SMC patient population 220/310 (71%) were successfully PCR analyzed. In the SMC children, the prevalence of all molecular markers of SP resistance increased significantly after SMC including the Pfdhfr-dhps quintuple mutant genotype, which was 1.6% before but 7.1% after SMC (p = 0.02). The prevalence of Pfmdr1-86Y significantly decreased from 26.7% to 15.3% (p = 0.04) while no significant change was seen for Pfcrt 76T. In 2014, prevalence of all molecular markers of SP resistance were significantly higher among SMC children compared to the non-SMC population patient (p < 0.01). No Pfdhfr-164 mutation was found neither at baseline nor post SMC.

Conclusion: SMC increased the prevalence of molecular markers of P. falciparum resistance to SP in the treated children. However, there was no significant increase of these markers of resistance in the general parasite population after 2 years and 7 rounds of SMC.

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. World Health Organization. World Malaria Report. Nature. 2013. doi:ISBN 978 92 4 1564403.
    1. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, et al. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet. 2009;374, 1533–1542. 10.1016/S0140-6736(09)61258-7
    1. World Health Organization (WHO) policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa WHO, 2012; Geneva, Switzerland.
    1. Ecker A, Lehane AM, Clain J, Fidock DA. PfCRT and its role in antimalarial drug resistance. Trends Parasitol. 2012;28:504–514. 10.1016/j.pt.2012.08.002
    1. Gregson A, Plowe CV. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 2005;57:117–145.
    1. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT, et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet. 2007;369: 491–498.
    1. Cissé B, Sokhna C, Boulanger D, Milet J, Bâ el H, Richardson K, et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: A randomised, placebo-controlled, double-blind trial. Lancet. 2006;367, 659–667.
    1. Kweku M, Liu D, Adjuik M, Binka F, Seidu M, Greenwood B, et al. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: a randomized, placebo controlled trial. PLoS ONE. 2008;3(12): e4000 10.1371/journal.pone.0004000
    1. Lo AC, Faye B, Ba el-H, Cisse B, Tine R, Abiola A, et al. Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal. Malar J. 2013;12: 137 10.1186/1475-2875-12-137
    1. Somé AF, Zongo I, Compaoré YD, Sakandé S, Nosten F, Ouédraogo JB, et al. Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2014;58(7) 3660–5. 10.1128/AAC.02406-14
    1. Zongo I, Milligan P, Compaore YD, Some AF, Greenwood B, Tarning J, et al. Randomized Non-inferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob Agents Chemother. 2015;59(8): 4387–96. 10.1128/AAC.04923-14
    1. Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Dicko Y, et al. Intermittent Preventive Treatment of Malaria Provides Substantial Protection against Malaria in Children Already Protected by an Insecticide-Treated Bednet in Mali: A Randomised, Double-Blind, Placebo-Controlled Trial. PLoS Med. 2011;8(2): e1000407 10.1371/journal.pmed.1000407
    1. Konate´ AT, Yaro JB, Ouedraogo AZ, Diarra A, Gansané A, Soulama I, et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomized, double blind, and placebo controlled trial. PLoS Med. 2011;8(2): e1000408 10.1371/journal.pmed.1000408
    1. Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am. J. Trop. Med. Hyg. 2008;78, 455–461.
    1. Ndiaye D, Daily JP, Sarr O, Ndir O, Gaye O, Mboup S, et al. Defining the origin of Plasmodium falciparum resistant dhfr isolates in Senegal. Acta Trop. 2006;99, 106–111
    1. Tinto H, Ouédraogo JB, Zongo I, van Overmeir C, van Marck E, Guiguemdé TR, et al. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am. J. Trop. Med. Hyg. 2007;76, 608–613.
    1. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J Infect Dis. 2002;185(3):380–8.
    1. Shah M, Omosun Y, Lal A, Odero C, Gatei W, Otieno K, et al. Assessment of molecular markers for anti-malarial drug resistance after the introduction and scale-up of malaria control interventions in western Kenya. Malar J. 2015;14: 75 10.1186/s12936-015-0588-4
    1. Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, et al. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Malar J. 2012;11:134 10.1186/1475-2875-11-134
    1. Mbugi EV, Mutayoba BM, Malisa AL, Balthazary ST, Nyambo TB, Mshinda H. Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. Malar J. 2006;5:94
    1. Aubouy A, Jafari S, Huart V, Migot-Nabias F, Mayombo J, Durand R, et al. DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. J Antimicrob Chemother. 2003;52(1):43–9.
    1. Nfor ENMW, Njifutri N, Mbulli IA, Tawé B, Masumbi NP, Venyoka A. Evaluation de la chimiorésistance à la sulfadoxine-pyrimethamine et des mutations des genes dhfr et dhps dans le district de sante de Ndu au nord-ouest Cameroun. Afr J Sci Tech. 2007;8, 52–55.
    1. Faye B, Ndiaye M, Ndiaye JL, Annie A, Tine RC, Lo AC, et al. Prevalence of molecular markers of Plasmodium falciparum resistance to sulfadoxine-pyrimethamine during the intermittent preventive treatment in infants coupled with the expanded program immunization in Senegal. Parasitol Res. 2011;109(1):133–8. 10.1007/s00436-010-2236-9
    1. Mockenhaupt FP, Teun Bousema J, Eggelte TA, Schreiber J, Ehrhardt S, Wassilew N, et al. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Trop Med Int Health. 2005;10(9):901–8.
    1. Dokomajilar C, Lankoande ZM, Dorsey G, Zongo I, Ouedraogo JB, Rosenthal PJ. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am J Trop Med Hyg. 2006;75(1):162–5.
    1. Diallo DA, Sutherland C, Nebie I, Konate AT, Ord R, Ilboudo-Sanogo E, et al. Children in Burkina Faso who are protected by insecticide-treated materials are able to clear drug-resistant parasites better than unprotected children. J Infect Dis. 2007;196(1):138–44.
    1. Marks F, Evans J, Meyer CG, Browne EN, Flessner C, von Kalckreuth V, et al. High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana. Antimicrob Agents Chemother. 2005;49(3):1101–5.
    1. Bonnet M, Roper C, Félix M, Coulibaly L, Kankolongo GM, Guthmann JP. Efficacy of antimalarial treatment in Guinea: in vivo study of two artemisinin combination therapies in Dabola and molecular markers of resistance to sulphadoxine-pyrimethamine in N'Zérékoré. Malar J. 2007;6:54
    1. Sisowath C, Petersen I, Veiga MI, Mårtensson A, Premji Z, Björkman A, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis. 2009;199(5):750–7. 10.1086/596738
    1. Achieng AO, Muiruri P, Ingasia LA, Opot BH, Juma DW, Yeda R, et al. Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya. Int J Parasitol Drugs Drug Resist. 2015;5(3):92–9. 10.1016/j.ijpddr.2015.05.005
    1. Kiaco K, Teixeira J, Machado M, do Rosário V, Lopes D. Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola. Malar J. 2015;14:504 10.1186/s12936-015-1018-3
    1. Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, et al. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. Acta Trop. 2005;95:183–93.
    1. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect Genet Evol. 2006;6(4):309–14.
    1. Nawaz F., Nsobya S. L., Kiggundu M., Joloba M. & Rosenthal P. J. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J. Infect. Dis. 2009;200,1650–1657. 10.1086/647988
    1. Watkins WM, Mosobo M. Treatment of Plasmodium falciparum malaria with pyrimethamine-sulfadoxine: selective pressure for resistance is a function of long elimination half-life. Trans R Soc Trop Med Hyg. 1993;87(1):75–8.
    1. Diourté Y, Djimdé A, Doumbo OK, Sagara I, Coulibaly Y, Dicko A, et al. Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg. 1999;60(3):475–8.
    1. Djimdé AA, Doumbo OK, Traore O, Guindo AB, Kayentao K, Diourte Y, et al. Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am J Trop Med Hyg. 2003;69(5):558–63.
    1. Ogouyèmi-Hounto A, Tuikue NN, Kinde GD, d’Almeida S, Koussihoude L, Ollo Elvire, et al. Prevalence of the molecular marker of Plasmodium falciparum resistance to chloroquine and sulphadoxine/pyrimethamine in Benin seven years after the change of malaria treatment policy. Malar J. 2013;12:147 10.1186/1475-2875-12-147
    1. World Health Organization: Defining and validating a measure of parasite resistance to sulfadoxine-pyrimethamine (SP) that would be indicative of the protective efficacy of SP for intermittent preventive treatment in infancy (SP-IPTi); 2009.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere